The Global Viral vector vaccine manufacturing market is anticipated to grow at a CAGR of 18.19% between 2019 and 2027. Viral vector vaccines are a radical new approach in vaccination that uses live viruses to carry DNA into human cells. The important drivers increasing growth in the global viral vector vaccine manufacturing Market are Promising results from several clinical studies and growing chronic diseases. Viral-vector-based clinical trials initiated a surge of investments in drug development and commercialization. Several clinical trials for viral-vector-based medicine are being carried out by various institutes and other research centers to check its utility in medication for treatment.

GLOBAL VIRAL VECTOR VACCINE MANUFACTURING MARKET FORECAST 2019-2027

Global Viral Vector Vaccines Manufacturing Market by Types 2019-2027 (Adenoviral Vectors, Retroviral Vectors, Lent Viral Vectors, Adeno-associated Viral Vectors, Poxvirus, Cytomegalovirus, Other Viral Vectors) by Application (Multivalent, Multipathogen) by Diseases (Human Diseases, Veterinary Diseases) by Geography.

Request free sample

Report Summary

The global viral vector vaccine manufacturing market is anticipated to grow at a CAGR of 18.19% between 2019 and 2027. Viral vector vaccines are a radical new approach in vaccination that uses live viruses to carry DNA into human cells. The Viral vector vaccine manufacturing market is primarily driven by the following factors:

Promising results from several clinical studies
The mounting number of viral vectors gene-therapy-based clinical trials
Growing chronic diseases

Viral Vector Vaccine Manufacturing Market

To know more about this report, request a free sample copy.

The important drivers increasing growth in the global viral vector vaccine manufacturing market are promising results from several clinical studies and growing chronic diseases. Viral-vector-based clinical trials initiated a surge of investments in drug development and commercialization. Several clinical trials for viral-vector based medicine are being carried out by various institutes and other research centres to check its utility in medication for treatment. The growing prevalence of chronic diseases is leading to increased demand for viral vector vaccines. The most prevalent chronic diseases are cancer, cardiovascular disease, tuberculosis, HIV and others.

The types of viral vector vaccine manufacturing market are used extensively for various purposes. Adenoviral vector has become a majorly exploited vector for advanced vaccine development. The advancements in the retroviral vector are expected to boost the global viral vector vaccine manufacturing market’s retroviral vector segment. Retrovirals have several key characteristics compared to conventional modes of gene delivery such as microinjection, electroporation, and transfection. Lent viral vector is also a type of retroviral vector that can infect both non-dividing and dividing cells since the pre-integration complex formed, which is also referred to as virus shell and can simply penetrate the integral membrane of the nucleus of a targeted cell. There are several ongoing clinical trials with AAV vector for development of a vaccine to treat eye and muscle diseases. Poxvirus is the most commonly known DNA virus and is distinguished from other viruses through its capability to reproduce completely in the cytoplasm available across the host cell and present external to the nucleus. Cytomegalovirus has extensive application in the development of notably precise and cost-effective vaccines for the treatment of diseases such as HIV/AIDS and cancer.

Poor reimbursement system and stringent government policies are the major factors hindering the viral vector vaccine manufacturing market. The poor reimbursement system is a major restraint which restricts the individuals to go for cancer detection tests and affects viral vaccines market constituting cancer in a negative way. Government policies must be favourable for research and development to help in the growth of the market.

The Global Viral vector vaccine manufacturing market segments include types, diseases, and applications.

Types are segmented into:

Adenoviral vectors
Retroviral vectors
Lent viral vectors
Adeno-associated viral vectors
Poxvirus
Cytomegalovirus
Other viral vectors

Diseases are segmented into:

Human diseases
- Hepatitis
- Cancer
- Malaria
- Tuberculosis
- Influenza
- HIV
- Other human diseases
Veterinary diseases
- Avian influenza
- Marek’s disease
- Infectious bronchitis
- PPR disease
- Other veterinary diseases

Applications are segmented into:

Multivalent
Multi-pathogen

This report covers the present market conditions and the growth prospects of the global viral vector vaccine manufacturing market for 2019-2027 and considered the revenue generated through the sales of Viral vector vaccine manufacturing by types, diseases, and applications to calculate the market size by considering 2018 as the base year.

Geographically, the global viral vector vaccine manufacturing market has been segmented on the basis of four major regions, which include:

North America Viral Vector Vaccines Manufacturing Market: The United States & Canada
Asia-Pacific Viral Vector Vaccines Manufacturing Market: China, India, Japan, Australia, South Korea & Rest of APAC
Europe Viral Vector Vaccines Manufacturing Market: The United Kingdom, France, Germany, Spain, Italy & Rest of Europe
Rest of World: Latin America and the Middle East and Africa

The Viral vector vaccine manufacturing market in Europe is expected to hold the largest share by 2027 on account of the growing R&D expenditure for viral vectors, and the growing number of livestock diseases in Europe. A rise in the HPAI outbreaks in domestic birds in the region is also fueling the adoption of viral-vector-based vaccines, thereby driving the market for viral vector vaccine manufacturing. On the other hand, the North America market is anticipated to be the fastest-growing region for the global viral vector vaccine manufacturing market. The North America viral vector vaccine manufacturing market is primarily driven by the rising clinical trials in viral vectors and increasing government funding in cancer research. Moreover, the high prevalence of genetic disorders and chronic diseases and government investment in gene-editing tools and research funding for gene research are also fueling the market growth.

The viral vector vaccine manufacturing market is segmented on the basis of diseases which are sub-divided into human diseases and veterinary diseases. The application segment of the market is sub-divided into multivalent and multi-pathogen. The multivalent viral vectors possess the property of having various antigens that prove beneficial for prevention against diseases. The multi-pathogen viral vector vaccines present antigen in a unique way and are capable of expressing various transgenes at once. Viral vector vaccines have potential application in the prevention and protection of humans from diseases such as influenza, cancer, and tuberculosis. Viral vector systems that have been premeditated in vaccinology are adeno-associated virus vectors and poxvirus vectors. Viral-vectored vaccines, specifically using vectors such as pox virus, herpes virus, and adenovirus are increasingly being used in veterinary medicine, where viral vector technology has been adopted more rapidly than in human medicine.

The major market players of the global viral vector vaccine manufacturing market are:

Biogen Idec (Now Biogen Inc.)
Advanced Bioscience Laboratories Inc.
Batavia Biosciences
Cobra Biologics (Subsidiary Of Recip Ab)
GE Healthcare

Company Profiles covers analysis of important players.

Biogen Inc. (or ‘the company’), formerly known as Biogen Idec, a biopharmaceutical company, focuses on the development, manufacturing and delivering therapies for neurological, autoimmune and hematologic disorders. GE Healthcare (or ‘the company’) is a medical technology business unit of General Electric (GE). The unit is a global provider of medical technologies and services for the diagnosis and treatment of cancer, heart disease, neurological diseases, women’s health, and other conditions.

Key Findings of the Global Viral vector vaccine manufacturing market:

Poxvirus constitutes the largest market share in terms of types
Human diseases are anticipated to grow significantly during the forecast period
Multivalent applications are widely used in the viral vector manufacturing market

RESEARCH SCOPE
- STUDY GOALS
- SCOPE OF THE MARKET STUDY
- WHO WILL FIND THIS REPORT USEFUL?
- STUDY AND FORECASTING YEARS
RESEARCH METHODOLOGY
- SOURCES OF DATA
  - SECONDARY DATA
  - PRIMARY DATA
- TOP DOWN APPROACH
- BOTTOM-UP APPROACH
- DATA TRIANGULATION
EXECUTIVE SUMMARY
- MARKET SUMMARY
- KEY FINDINGS
  - POX VIRUS CONSTITUTES THE LARGEST MARKET SHARE IN TERMS OF TYPES
  - HUMAN DISEASES ARE ANTICIPATED TO GROW SIGNIFICANTLY DURING THE FORECAST PERIOD
  - MULTIVALENT APPLICATIONS ARE WIDELY USED IN THE VIRAL VECTOR MANUFACTURING MARKET

MARKET DETERMINANTS
- MARKET DRIVERS
  - PROMISING RESULTS FROM SEVERAL CLINICAL STUDIES
  - MOUNTING NUMBER OF VIRAL VECTORS GENE-THERAPY-BASED CLINICAL TRIALS
  - GROWING CHRONIC DISEASES
- MARKET OPPORTUNITIES
  - SWELLING INVESTMENT IN GENE-THERAPY-BASED R&D ACTIVITIES
  - INCREASE IN THE RESEARCH AND DEVELOPMENT
- MARKET RESTRAINTS
  - POOR REIMBURSEMENT SYSTEM
  - STRINGENT GOVERNMENT POLICIES
- MARKET CHALLENGES
  - UNFAVOURABLE COMPENSATION SITUATION
  - PRICING PRESSURE COUPLED WITH LACK OF PRODUCT DIFFERENTIATION
  - RIGOROUS REGULATORY AGENDA

MARKET SEGMENTATION
- MARKET BY TYPES 2019-2027
  - ADENOVIRAL VECTORS
  - RETROVIRAL VECTORS
  - LENTIVIRAL VECTORS
  - ADENO-ASSOCIATED VIRAL VECTORS
  - POXVIRUS
  - CYTOMEGALOVIRUS
  - OTHER VIRAL VECTORS
- MARKET BY APPLICATION 2019-2027
  - MULTIVALENT
  - MULTIPATHOGEN
- MARKET BY DISEASES 2019-2027
  - HUMAN DISEASES
    - HEPATITIS
    - CANCER
    - MALARIA
    - TUBERCULOSIS
    - INFLUENZA
    - HIV
    - OTHER HUMAN DISEASES
  - VETERINARY DISEASES
    - AVIAN INFLUENZA
    - MAREK’S DISEASE
    - INFECTIOUS BRONCHITIS
    - PPR DISEASE
    - OTHER VETERINARY DISEASES

KEY ANALYTICS
- EVOLUTION AND TRANSITION
- REGULATORY FRAMEWORK
  - THE UNITED STATES
  - EUROPEAN UNION
  - ASIA PACIFIC
    - AUSTRALIA
    - JAPAN
    - INDIA
    - CHINA
  - KEY PROPERTIES OF VIRAL VECTOR
  - CHARACTERISTICS OF POTENTIAL VIRAL VACCINE VECTORS
  - PATENT ANALYSIS
    - THE UNITED STATES PATENT ANALYSIS
    - EUROPE PATENT ANALYSIS
    - JAPAN PATENT ANALYSIS
  - MANUFACTURING PROCESS OF A VIRAL-VECTOR
  - SMALL-SCALE MANUFACTURING PROCESS OF ADENOVIRUS
  - KEY SUPPLIERS IN VIRAL VECTOR MARKET
  - KEY BUYING CRITERIA

GEOGRAPHICAL ANALYSIS
- NORTH AMERICA
  - THE UNITED STATES
  - CANADA
- EUROPE
  - GERMANY
  - THE UNITED KINGDOM
  - FRANCE
  - SPAIN
  - ITALY
  - REST OF THE EUROPE
- ASIA-PACIFIC
  - CHINA
  - INDIA
  - JAPAN
  - AUSTRALIA
  - SOUTH KOREA
  - REST OF ASIA-PACIFIC
- REST OF THE WORLD
  - LATIN AMERICA
  - MIDDLE EAST AND AFRICA

COMPANY PROFILES
- ADVANCED BIOTHERAPEUTICS CONSULTING
- ADVANCED BIOSCIENCE LABORATORIES INC.
- APPLIED VIROMICS
- BATAVIA BIOSCIENCES
- BENITEC BIOPHARMA
- BIOGEN IDEC (NOW BIOGEN INC.)
- BIOVIAN
- BRAMMER BIO
- BOEHRINGER INGELHEIM GMBH
- CELL AND GENE THERAPY CATAPULT
- CEVA CORPORATE
- COBRA BIOLOGICS (SUBSIDIARY OF RECIP AB)
- GE HEALTHCARE
- JANSSEN PHARMACEUTICAL INC.
- ID PHARMA CO. LTD.

LIST OF TABLES

TABLE 1 GLOBAL VIRAL VECTOR VACCINE MANUFACTURING MARKET BY GEOGRAPHY 2019-2027 ($ THOUSAND)

TABLE 2 ONGOING CLINICAL TRIALS RELATED TO VIRAL VECTORS

TABLE 3 VARIOUS VIRAL VECTORS PROPERTIES AND THEIR APPLICATION IN GENE THERAPY

TABLE 4 GLOBAL VIRAL VECTOR VACCINE MANUFACTURING MARKET BY TYPES 2019-2027 ($ THOUSANDS)

TABLE 5 KEY VIRAL VECTORS CHARACTERISTICS

TABLE 6 GLOBAL VIRAL VECTOR VACCINE MANUFACTURING MARKET IN ADENOVIRAL VECTORS BY GEOGRAPHY 2019-2027 ($ THOUSANDS)

TABLE 7 GLOBAL VIRAL VECTOR VACCINE MANUFACTURING MARKET IN RETROVIRAL VECTORS BY GEOGRAPHY 2019-2027 ($ THOUSANDS)

TABLE 8 ADVANTAGES AND DISADVANTAGES OF RETROVIRAL VECTORS

TABLE 9 COMPONENTS OF HIV PROVIRUS

TABLE 10 GLOBAL VIRAL VECTOR VACCINE MANUFACTURING MARKET IN LENTIVIRAL VECTORS BY GEOGRAPHY 2019-2027 ($ THOUSANDS)

TABLE 11 SECOND- VS. THIRD-GENERATION LENTIVIRAL SYSTEMS

TABLE 12 AAV VECTORS WITH THEIR TROPISMS AND RECEPTORS

TABLE 13 GLOBAL VIRAL VECTOR VACCINE MANUFACTURING MARKET IN ADENO-ASSOCIATED VIRAL VECTORS BY GEOGRAPHY 2019-2027 ($ THOUSANDS)

TABLE 14 LICENSED FOWL POX VIRAL-VECTORED VETERINARY VACCINES

TABLE 15 GLOBAL VIRAL VECTOR VACCINE MANUFACTURING MARKET IN POX VIRUS BY GEOGRAPHY 2019-2027 ($ THOUSANDS)

TABLE 16 GLOBAL VIRAL VECTOR VACCINE MANUFACTURING MARKET IN CYTOMEGALOVIRUS BY GEOGRAPHY 2019-2027 ($ THOUSANDS)

TABLE 17 GLOBAL VIRAL VECTOR VACCINE MANUFACTURING MARKET IN OTHER VIRAL VECTORS BY GEOGRAPHY 2019-2027 ($ THOUSANDS)

TABLE 18 GLOBAL VIRAL VECTOR VACCINE MANUFACTURING MARKET BY APPLICATION 2019-2027 ($ THOUSANDS)

TABLE 19 GLOBAL VIRAL VECTOR VACCINE MANUFACTURING MARKET IN MULTIVALENT BY GEOGRAPHY 2019-2027 ($ THOUSANDS)

TABLE 20 REGION WISE TB STATISTICS FOR 2016

TABLE 21 GLOBAL VIRAL VECTOR VACCINE MANUFACTURING MARKET IN MULTIPATHOGEN BY GEOGRAPHY 2019-2027 ($ THOUSANDS)

TABLE 22 GLOBAL VIRAL VECTOR VACCINE MANUFACTURING MARKET BY DISEASES 2019-2027 ($ THOUSANDS)

TABLE 23 GLOBAL VIRAL VECTOR VACCINE MANUFACTURING MARKET IN HUMAN DISEASES BY GEOGRAPHY 2019-2027 ($ THOUSANDS)

TABLE 24 GLOBAL VIRAL VECTOR VACCINE MANUFACTURING MARKET IN HUMAN DISEASES BY TYPES 2019-2027 ($ THOUSANDS)

TABLE 25 GLOBAL HUMAN DISEASES MARKET IN HEPATITIS BY GEOGRAPHY 2019-2027 ($ THOUSANDS)

TABLE 26 ESTIMATED ACTUAL NEW CASES OF HAV

TABLE 27 GLOBAL HUMAN DISEASES MARKET IN CANCER BY GEOGRAPHY 2019-2027 ($ THOUSANDS)

TABLE 28 ESTIMATED NEW CANCER CASES IN THE UNITED STATES 2017

TABLE 29 GLOBAL HUMAN DISEASES MARKET IN MALARIA BY GEOGRAPHY 2019-2027 ($ THOUSANDS)

TABLE 30 MALARIA VACCINE DEVELOPMENT INITIATIVES

TABLE 31 VIRAL VECTOR VACCINE CANDIDATES FOR TUBERCULOSIS

TABLE 32 GLOBAL HUMAN DISEASES MARKET IN TUBERCULOSIS BY GEOGRAPHY 2019-2027 ($ THOUSANDS)

TABLE 33 GLOBAL HUMAN DISEASES MARKET IN INFLUENZA BY GEOGRAPHY 2019-2027 ($ THOUSANDS)

TABLE 34 BENEFITS AND CONCERN FOR VIRUS-VECTORED EXPERIMENTAL INFLUENZA VACCINES

TABLE 35 GLOBAL HUMAN DISEASES MARKET IN HIV BY GEOGRAPHY 2019-2027 ($ THOUSANDS)

TABLE 36 GLOBAL HUMAN DISEASES MARKET IN OTHER HUMAN DISEASES BY GEOGRAPHY 2019-2027 ($ THOUSANDS)

TABLE 37 ONGOING CLINICAL TRIALS AND DEVELOPMENT IN ZIKA VIRUS VACCINE

TABLE 38 LICENSED VIRAL-VECTORED VETERINARY VACCINES

TABLE 39 GLOBAL VIRAL VECTOR VACCINE MANUFACTURING MARKET IN VETERINARY DISEASES BY GEOGRAPHY 2019-2027 ($ THOUSANDS)

TABLE 40 GLOBAL VIRAL VECTOR VACCINE MANUFACTURING MARKET IN VETERINARY DISEASES BY TYPES 2019-2027 ($ THOUSANDS)

TABLE 41 AVIAN INFLUENZA VACCINES

TABLE 42 GLOBAL VETERINARY DISEASES MARKET IN AVIAN INFLUENZA BY GEOGRAPHY 2019-2027 ($ THOUSANDS)

TABLE 43 GLOBAL VETERINARY DISEASES MARKET IN MAREK’S DISEASE BY GEOGRAPHY 2019-2027 ($ THOUSANDS)

TABLE 44 MAREK’S DISEASE VACCINES

TABLE 45 GLOBAL VETERINARY DISEASES MARKET IN INFECTIOUS BRONCHITIS BY GEOGRAPHY 2019-2027 ($ THOUSANDS)

TABLE 46 GLOBAL VETERINARY DISEASES MARKET IN PPR DISEASE BY GEOGRAPHY 2019-2027 ($ THOUSANDS)

TABLE 47 GLOBAL VETERINARY DISEASES MARKET IN OTHER VETERINARY DISEASES BY GEOGRAPHY 2019-2027 ($ THOUSANDS)

TABLE 48 GLOBAL VIRAL VECTOR VACCINE MANUFACTURING MARKET BY GEOGRAPHY 2019-2027 ($ THOUSANDS)

TABLE 49 NORTH AMERICA VIRAL VECTOR VACCINE MANUFACTURING MARKET 2019-2027 ($ THOUSANDS)

TABLE 50 FUNDING IN CANCER RESEARCH IN THE UNITED STATES ($ MILLIONS)

TABLE 51 THE UNITED STATES VIRAL VECTOR VACCINE MANUFACTURING MARKET BY TYPES 2019-2027 ($ THOUSANDS)

TABLE 52 NIH FUNDING FOR CRISPR-RELATED RESEARCH 2006-2016 ($)

TABLE 53 CANADA VIRAL VECTOR VACCINE MANUFACTURING MARKET BY TYPES 2019-2027 ($ THOUSANDS)

TABLE 54 EUROPE VIRAL VECTOR VACCINE MANUFACTURING MARKET 2019-2027 ($ THOUSANDS)

TABLE 55 GERMANY VIRAL VECTOR VACCINE MANUFACTURING MARKET 2019-2027 BY TYPES ($ THOUSANDS)

TABLE 56 THE UNITED KINGDOM VIRAL VECTOR VACCINE MANUFACTURING MARKET BY TYPES 2019-2027 ($ THOUSANDS)

TABLE 57 FRANCE VIRAL VECTOR VACCINE MANUFACTURING MARKET BY TYPES 2019-2027 ($ THOUSANDS)

TABLE 58 SPAIN VIRAL VECTOR VACCINE MANUFACTURING MARKET BY TYPES 2019-2027 ($ THOUSANDS)

TABLE 59 ITALY VIRAL VECTOR VACCINE MANUFACTURING MARKET BY TYPES 2019-2027 ($ THOUSANDS)

TABLE 60 ASIA-PACIFIC VIRAL VECTOR VACCINE MANUFACTURING MARKET 2019-2027 ($ THOUSANDS)

TABLE 61 CHINA VIRAL VECTOR VACCINE MANUFACTURING MARKET 2019-2027 BY TYPES ($ THOUSANDS)

TABLE 62 ONGOING PRECLINICAL AND CLINICAL TRIALS OF HIV/AIDS VACCINE IN CHINA

TABLE 63 PREVALENCE OF TUBERCULOSIS IN INDIA 2016

TABLE 64 INDIAVIRAL VECTOR VACCINE MANUFACTURING MARKET 2019-2027 BY TYPES ($ THOUSANDS)

TABLE 65 CLINICAL TRIALS RELATED TO HIV VACCINE IN INDIA

TABLE 66 JAPAN VIRAL VECTOR VACCINE MANUFACTURING MARKET 2019-2027 BY TYPES ($ THOUSANDS)

TABLE 67 AUSTRALIA VIRAL VECTOR VACCINE MANUFACTURING MARKET 2019-2027 BY TYPES ($ THOUSANDS)

TABLE 68 SOUTH KOREA VIRAL VECTOR VACCINE MANUFACTURING MARKET 2019-2027 BY TYPES ($ THOUSANDS)

TABLE 69 PRINCIPAL CAUSES OF DEATHS IN SINGAPORE, 2014–2016

TABLE 70 NUMBER OF HIV AND AIDS PEOPLE IN THAILAND 2016

TABLE 71 REST OF WORLD VIRAL VECTOR VACCINE MANUFACTURING MARKET 2019-2027 ($ THOUSANDS)

TABLE 72 LATIN AMERICA VIRAL VECTOR VACCINE MANUFACTURING MARKET 2019-2027 BY TYPES ($ THOUSANDS)

TABLE 73 CAUSES OF DEATH IN CUBA AND PERCENTAGE CHANGE FROM 2005-2016

TABLE 74 MIDDLE EAST AND AFRICA VIRAL VECTOR VACCINE MANUFACTURING MARKET 2019-2027 BY TYPES ($ THOUSANDS)

TABLE 75 CHARACTERISTICS OF THE PRIORITY DISEASES IDENTIFIED BY THE WHO R&D BLUEPRINT IN MEA 2017

LIST OF FIGURES

FIGURE 1 GLOBAL VIRAL VECTOR VACCINE MANUFACTURING MARKET 2019-2027 ($ THOUSAND)

FIGURE 2 SCHEMATIC OVERVIEW OF MULTIVALENT AND MULTIPATHOGEN VIRAL VECTOR VACCINES

FIGURE 3 REGION WISE ESTIMATION OF PEOPLE LIVING WITH HIV 2016 (MILLION)

FIGURE 4 REGION WISE PREVALENCE OF HBV INFECTION IN THE GENERAL POPULATION 2015 (MILLIONS)

FIGURE 5 CONFIRMED, PROBABLE AND SUSPECTED EVD CASES WORLDWIDE

FIGURE 6 POULTRY PRODUCTION ESTIMATES WORLDWIDE (MILLION METRIC TONS)

FIGURE 7 VACCINE ADVANCEMENTS TIMELINE

FIGURE 8 STEPS REQUIREMENT FOR VACCINE APPROVAL

FIGURE 9 VACCINE REVIEW AND REGULATION STEPS UNDER FDA

FIGURE 10 VACCINE REVIEW AND REGULATION STEPS UNDER EMA

FIGURE 11 VACCINE REVIEW AND REGULATION STEPS UNDER MHLW

FIGURE 12 APPROVAL PROCESS OF VACCINE IN INDIA

FIGURE 13 MANUFACTURING PROCESS OF ADENOVIRUS

FIGURE 14 THE UNITED STATES VIRAL VECTOR VACCINE MANUFACTURING MARKET 2019-2027 ($ THOUSANDS)

FIGURE 15 CANADA VIRAL VECTOR VACCINE MANUFACTURING MARKET 2019-2027 ($ THOUSANDS)

FIGURE 16 GERMANY VIRAL VECTOR VACCINE MANUFACTURING MARKET 2019-2027 ($ THOUSANDS)

FIGURE 17 THE UNITED KINGDOM VIRAL VECTOR VACCINE MANUFACTURING MARKET 2019-2027 ($ THOUSANDS)

FIGURE 18 NUMBER OF PEOPLE LIVING WITH HIV IN FRANCE

FIGURE 19 FRANCE VIRAL VECTOR VACCINE MANUFACTURING MARKET 2019-2027 ($ THOUSANDS)

FIGURE 20 LEADING CAUSES OF WOMEN DEATH IN FRANCE (%)

FIGURE 21 LEADING CAUSES OF MEN DEATH IN FRANCE (%)

FIGURE 22 SPAIN VIRAL VECTOR VACCINE MANUFACTURING MARKET 2019-2027 ($ THOUSANDS)

FIGURE 23 NUMBER OF PEOPLE IN SPAIN INFECTED WITH HIV

FIGURE 24 ITALY VIRAL VECTOR VACCINE MANUFACTURING MARKET 2019-2027 ($ THOUSANDS)

FIGURE 25 REST OF THE EUROPE VIRAL VECTOR VACCINE MANUFACTURING MARKET 2019-2027 ($ THOUSANDS)

FIGURE 26 NUMBER OF PEOPLE IN REST OF EUROPE INFECTED WITH HIV (THOUSANDS)

FIGURE 27 CHINA VIRAL VECTOR VACCINE MANUFACTURING MARKET 2019-2027 ($ THOUSANDS)

FIGURE 28 INDIA VIRAL VECTOR VACCINE MANUFACTURING MARKET 2019-2027 ($ THOUSANDS)

FIGURE 29 JAPAN VIRAL VECTOR VACCINE MANUFACTURING MARKET 2019-2027 ($ THOUSANDS)

FIGURE 30 NUMBER OF HIV CASES IN JAPAN 2012 AND 2016

FIGURE 31 AUSTRALIA VIRAL VECTOR VACCINE MANUFACTURING MARKET 2019-2027 ($ THOUSANDS)

FIGURE 32 VARIOUS VIRAL VACCINE VECTORS USED IN AIDS VACCINE DEVELOPMENT

FIGURE 33 NUMBER OF DIAGNOSED HIV INFECTIONS IN AUSTRALIA 2012–2016

FIGURE 34 SOUTH KOREA VIRAL VECTOR VACCINE MANUFACTURING MARKET 2019-2027 ($ THOUSANDS)

FIGURE 35 SHARES OF DEATH IN SOUTH KOREA IN 2016 DEATH RATE (PER 100,000 POPULATIONS)

FIGURE 36 REST OF ASIA-PACIFIC VIRAL VECTOR VACCINE MANUFACTURING MARKET 2019-2027 ($ THOUSANDS)

FIGURE 37 DIAGNOSED HIV CASES IN THE PHILIPPINES BY AGE GROUP 2016 (%)

FIGURE 38 LATIN AMERICA VIRAL VECTOR VACCINE MANUFACTURING MARKET 2019-2027 ($ THOUSANDS)

FIGURE 39 MIDDLE EAST AND AFRICA VIRAL VECTOR VACCINE MANUFACTURING MARKET 2019-2027 ($ THOUSANDS)

Segmentation

MARKET SEGMENTATION
- MARKET BY TYPES 2019-2027
  - ADENOVIRAL VECTORS
  - RETROVIRAL VECTORS
  - LENT VIRAL VECTORS
  - ADENO-ASSOCIATED VIRAL VECTORS
  - POXVIRUS
  - CYTOMEGALOVIRUS
  - OTHER VIRAL VECTORS
- MARKET BY APPLICATION 2019-2027
  - MULTIVALENT
  - MULTIPATHOGEN
- MARKET BY DISEASES 2019-2027
  - HUMAN DISEASES
    - HEPATITIS
    - CANCER
    - MALARIA
    - TUBERCULOSIS
    - INFLUENZA
    - HIV
    - OTHER HUMAN DISEASES
  - VETERINARY DISEASES
    - AVIAN INFLUENZA
    - MAREK’S DISEASE
    - INFECTIOUS BRONCHITIS
    - PPR DISEASE
    - OTHER VETERINARY DISEASES

GEOGRAPHICAL ANALYSIS
- NORTH AMERICA
  - THE UNITED STATES
  - CANADA
- EUROPE
  - GERMANY
  - THE UNITED KINGDOM
  - FRANCE
  - SPAIN
  - ITALY
  - REST OF THE EUROPE
- ASIA-PACIFIC
  - CHINA
  - INDIA
  - JAPAN
  - AUSTRALIA
  - SOUTH KOREA
  - REST OF ASIA-PACIFIC
- REST OF THE WORLD
  - LATIN AMERICA
  - MIDDLE EAST AND AFRICA